CHT101 is named as an intervention in 3 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Tianjin Medical University Cancer Institute and Hospital (1). The most-studied condition is Peripheral T-cell Lymphoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus
NCT06946485 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE)
|
Phase EARLY_PHASE1 | Recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | China |
|
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
NCT06914037 · ClinicalTrials.gov ↗ · Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL), NHL (Non-Hodgkin Lymphoma)
|
Phase 1 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | China |
|
A Clinical Study to Evaluate CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematologic Malignancies
NCT07809139 · ClinicalTrials.gov ↗ · Hematological Malignancies
|
Phase 1 | Not yet open | Nanjing Miracle Biotechnology Co., Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| Nanjing Miracle Biotechnology Co., Ltd. | 1 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 2 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China register name CHT101 (also registered as Universal anti-CD70 CAR-T) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Tianjin Medical University Cancer Institute and Hospital (1), Nanjing Miracle Biotechnology Co., Ltd (1) and The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how CHT101 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CHT101 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CHT101 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.